Comparative Pharmacology
Head-to-head clinical analysis: DEPACON versus PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPACON versus PHENYTOIN SODIUM.
DEPACON vs PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
Stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. Prolongs inactivation of voltage-gated sodium channels, reducing repetitive firing of action potentials.
10-15 mg/kg/day IV or orally divided every 8 hours; maximum 60 mg/kg/day.
Loading dose: 15-20 mg/kg IV (not to exceed 50 mg/min) or oral (1000-1500 mg total in divided doses). Maintenance: 300-400 mg/day PO in 1-2 divided doses or IV (100 mg every 6-8 hours).
None Documented
None Documented
10–16 hours; neonates 20–30 hours; patients with liver disease up to 18 hours; decreased half-life in patients on enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) to 4–9 hours.
Mean terminal half-life 22 ± 9 hours (range 7–42 hours), dose-dependent and saturable due to Michaelis-Menten kinetics; half-life increases with higher serum concentrations. Steady state achieved after 7–10 days.
Primarily renal: >90% of a dose is excreted in urine as valproic acid glucuronide (30–50%), 3-oxo-valproic acid (30–40%), and other metabolites. Less than 3% excreted unchanged. Minor fecal elimination (≈5%).
Primarily hepatic metabolism (CYP2C9, CYP2C19); <5% excreted unchanged in urine. Metabolites (majority p-HPPA) are excreted renally as glucuronide conjugates. Fecal elimination negligible (<2%).
Category C
Category D/X
Anticonvulsant
Anticonvulsant